Insight Molecular Diagnostics signals ~$8M quarterly cash burn in H2 2026 while targeting FDA authorization later this year (NASDAQ:IMDX)
· seekingalpha.com
IMDX Q2 2026 earnings call highlights: GraftAssureDx FDA timing, MolDX reimbursement tailwind, cash burn outlook, runway levers, and launch plans—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...